Welcome to our dedicated page for Mangoceuticals SEC filings (Ticker: MGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mangoceuticals, Inc. filings document a Nasdaq Capital Market-listed wellness telemedicine company, its MangoRx and PeachesRx brands, and securities issued to finance corporate operations. The company’s regulatory record includes Form 8-K reports on product communications, MGX-0024 data, branded GLP-1 program disclosures, litigation-related press releases, Nasdaq listing-rule notices and equity-compensation actions.
Registration statements and amendments describe the company’s securities offerings, capital structure, financial statements and risk disclosures. Other filings address common stock, warrants and pre-funded warrants, board and committee approvals, executive compensation arrangements, material events and forward-looking statement qualifications tied to Mangoceuticals’ telehealth platform, wellness products and public-company obligations.
Mangoceuticals, Inc. filed a Form 8-K reporting entry into a Mutual Rescission and Release Agreement with Navy Wharf, Ltd., effective July 30, 2025, terminating and rescinding the March 24, 2025 Master Distribution Agreement (MSA) that granted exclusive U.S./Canada licensing rights to Diabetinol trade dress and related IP.
Under the original MSA the Company issued 1,000,000 restricted shares to Navy Wharf and agreed to pay 10% of net sales as royalty. The Rescission Agreement provides mutual releases of obligations, requires Navy Wharf to cancel the Navy Shares, and states no material early termination penalties were incurred by the Company. Separately, on July 29, 2025 a warrant holder exercised for 198,000 shares at $1.50, raising $297,000; those shares were issued as 198,000 net shares under an exemption from registration. Exhibit 10.1 (Rescission Agreement) is filed.
Mangoceuticals has received a Notice of Effectiveness from the SEC for their Form S-3 registration statement, effective as of June 24, 2025, at 4:00 P.M. The Form S-3 (File Number: 333-288039) is a shelf registration statement that allows the company to offer and sell securities to the public.
A Form S-3 filing indicates that Mangoceuticals meets certain eligibility requirements, including being current with SEC reporting obligations. This registration enables the company to access capital markets more efficiently by allowing them to register securities for future public offerings. The effectiveness notice means the company can now proceed with securities offerings under this registration statement.
Filing highlight: Mangoceuticals, Inc. (CIK 0001938046; symbol MGRX) has received a formal Notice of Effectiveness from the U.S. Securities and Exchange Commission.
The SEC declared the company’s Form S-1 registration statement (File No. 333-287689) effective at 5:00 p.m. on June 18, 2025. This notice confirms that the registration statement has completed the Commission’s review and is now operative.
No further details—such as the size, terms, or purpose of the registered securities—were disclosed in the notice.